Polyak Andras, Bankstahl Jens P, Besecke Karen F W, Hozsa Constantin, Triebert Wiebke, Pannem Rajeswara Rao, Manstein Felix, Borcholte Thomas, Furch Marcus, Zweigerdt Robert, Gieseler Robert K, Bengel Frank M, Ross Tobias L
Department of Nuclear Medicine, Hannover Medical School, 30625 Hannover, Germany.
Rodos Biotarget GmbH, Medical Park Hannover, 30625 Hannover, Germany.
Pharmaceutics. 2021 Jul 18;13(7):1097. doi: 10.3390/pharmaceutics13071097.
In this work, a method for the preparation of the highly lipophilic labeling synthon [Zr]Zr(oxinate) was optimized for the radiolabeling of liposomes and human induced pluripotent stem cells (hiPSCs). The aim was to establish a robust and reliable labeling protocol for enabling up to one week positron emission tomography (PET) tracing of lipid-based nanomedicines and transplanted or injected cells, respectively. [Zr]Zr(oxinate) was prepared from oxine (8-hydroxyquinoline) and [Zr]Zr(OH)(CO). Earlier introduced liquid-liquid extraction methods were simplified by the optimization of buffering, pH, temperature and reaction times. For quality control, thin-layer chromatography (TLC), size-exclusion chromatography (SEC) and centrifugation were employed. Subsequently, the Zr-complex was incorporated into liposome formulations. PET/CT imaging of Zr-labeled liposomes was performed in healthy mice. Cell labeling was accomplished in PBS using suspensions of 3 × 10 hiPSCs, each. [Zr]Zr(oxinate) was synthesized in very high radiochemical yields of 98.7% (96.8% ± 2.8%). Similarly, high internalization rates (≥90%) of [Zr]Zr(oxinate) into liposomes were obtained over an 18 h incubation period. MicroPET and biodistribution studies confirmed the labeled nanocarriers' in vivo stability. Human iPSCs incorporated the labeling agent within 30 min with ~50% efficiency. Prolonged PET imaging is an ideal tool in the development of lipid-based nanocarriers for drug delivery and cell therapies. To this end, a reliable and reproducible Zr radiolabeling method was developed and tested successfully in a model liposome system and in hiPSCs alike.
在本研究中,针对脂质体和人诱导多能干细胞(hiPSC)的放射性标记,优化了一种制备高亲脂性标记合成子[Zr]Zr(8-羟基喹啉)的方法。目的是建立一种稳健且可靠的标记方案,分别实现基于脂质的纳米药物和移植或注射细胞长达一周的正电子发射断层扫描(PET)追踪。[Zr]Zr(8-羟基喹啉)由8-羟基喹啉(oxine)和[Zr]Zr(OH)(CO)制备而成。通过优化缓冲、pH值、温度和反应时间,简化了早期引入的液-液萃取方法。为进行质量控制,采用了薄层色谱(TLC)、尺寸排阻色谱(SEC)和离心法。随后,将Zr络合物掺入脂质体制剂中。对Zr标记的脂质体在健康小鼠体内进行了PET/CT成像。在PBS中使用每毫升3×10个hiPSC的悬浮液完成细胞标记。[Zr]Zr(8-羟基喹啉)的合成放射性化学产率非常高,达到98.7%(96.8%±2.8%)。同样,在18小时的孵育期内,[Zr]Zr(8-羟基喹啉)进入脂质体的内化率很高(≥90%)。微型PET和生物分布研究证实了标记纳米载体在体内的稳定性。人iPSC在30分钟内摄取标记剂的效率约为50%。长时间PET成像在开发用于药物递送和细胞治疗的基于脂质的纳米载体方面是一种理想工具。为此,开发了一种可靠且可重复的Zr放射性标记方法,并在模型脂质体系统和hiPSC中均成功进行了测试。